Patents by Inventor Stephen R. Jaspers

Stephen R. Jaspers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of IL-17A and IL-17F cross-reactive monoclonal antibodies for treating inflammatory diseases
    Patent number: 10640575
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, as well as methods of using the same in inflammation.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: May 5, 2020
    Assignee: ZymoGenetics, Inc.
    Inventors: Stephen R. Jaspers, Scott R. Presnell
  • Treating inflammation with IL-17/IL-23 bispecific antibodies
    Patent number: 10562967
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: February 18, 2020
    Assignee: ZymoGenetics, Inc.
    Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, Robert Mabry, Stephen R. Jaspers, Monica J. Huber
  • USE OF IL-17A AND IL-17F CROSS-REACTIVE MONOCLONAL ANTIBODIES FOR TREATING INFLAMMATORY DISEASES
    Publication number: 20180282433
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, as well as methods of using the same in inflammation.
    Type: Application
    Filed: June 15, 2018
    Publication date: October 4, 2018
    Inventors: Stephen R. Jaspers, Scott R. Presnell
  • TREATING INFLAMMATION WITH IL-17/IL-23 BISPECIFIC ANTIBODIES
    Publication number: 20180251541
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
    Type: Application
    Filed: May 8, 2018
    Publication date: September 6, 2018
    Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, Robert Mabry, Stephen R. Jaspers, Monica J. Huber
  • POLYNUCLEOTIDES ENCODING MONOCLONAL ANTIBODIES THAT BIND BOTH IL-17A AND IL-17F
    Publication number: 20180251543
    Abstract: The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.
    Type: Application
    Filed: May 15, 2018
    Publication date: September 6, 2018
    Inventors: Stephen R. Jaspers, Scott R. Presnell, Monica J. Huber
  • Methods of treating inflammation using IL-17A and IL-17F cross-reactive monoclonal antibodies
    Patent number: 10023656
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, as well as methods of using the same in inflammation.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: July 17, 2018
    Assignee: ZYMOGENETICS INC.
    Inventors: Stephen R. Jaspers, Scott R. Presnell
  • Monoclonal antibodies that bind both IL-17A and IL-17F
    Patent number: 10000563
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.
    Type: Grant
    Filed: July 12, 2016
    Date of Patent: June 19, 2018
    Assignee: ZYMOGENETICS, INC.
    Inventors: Stephen R. Jaspers, Scott R. Presnell, Monica J. Huber
  • Use of an IL-17/IL-23 bispecific antibody for treating inflammation
    Patent number: 9994634
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and IL-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: June 12, 2018
    Assignee: ZYMOGENETICS, INC.
    Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, Robert Mabry, Stephen R. Jaspers, Monica J. Huber
  • METHODS OF TREATING INFLAMMATION USING IL-17A AND IL-17F CROSS-REACTIVE MONOCLONAL ANTIBODIES
    Publication number: 20170233498
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, as well as methods of using the same in inflammation.
    Type: Application
    Filed: April 28, 2017
    Publication date: August 17, 2017
    Inventors: Stephen R. Jaspers, Scott R. Presnell
  • Antibodies that bind both IL-17A and IL-17F
    Patent number: 9663572
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, as well as methods of using the same in inflammation.
    Type: Grant
    Filed: November 4, 2015
    Date of Patent: May 30, 2017
    Assignee: ZYMOGENETICS INC.
    Inventors: Stephen R. Jaspers, Scott R. Presnell
  • ANTI-HUMAN IL-21 ANTIBODIES
    Publication number: 20170037123
    Abstract: Monoclonal antibodies are identified that bind the IL-21 protein. These antibodies are used to identify regions of the IL-21 protein to where binding neutralizes IL-21 activity. Hybridomas and methods of producing anti-IL-21 monoclonal antibodies are described. The monoclonal antibodies are useful in treating IL-21-mediated diseases, which may include autoimmune and inflammatory diseases such as pancreatitis, type I diabetes (IDDM), Graves Disease, inflammatory bowel disease (IBD), Crohn's Disease, ulcerative colitis, irritable bowel syndrome, multiple sclerosis, rheumatoid arthritis, diverticulosis, systemic lupus erythematosus, psoriasis, ankylosing spondylitis, scleroderma, systemic sclerosis, psoriatic arthritis, osteoarthritis, atopic dermatitis, vitiligo, graft vs.
    Type: Application
    Filed: June 9, 2016
    Publication date: February 9, 2017
    Inventors: Pallavur V. SIVAKUMAR, Stephen R. JASPERS
  • USE OF AN IL-17/IL-23 BISPECIFIC ANTIBODY FOR TREATING INFLAMMATION
    Publication number: 20160376362
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and IL-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
    Type: Application
    Filed: September 8, 2016
    Publication date: December 29, 2016
    Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, Robert Mabry, Stephen R. Jaspers, Monica J. Huber
  • MONOCLONAL ANTIBODIES THAT BIND BOTH IL-17A AND IL-17F
    Publication number: 20160311897
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.
    Type: Application
    Filed: July 12, 2016
    Publication date: October 27, 2016
    Inventors: Stephen R. Jaspers, Scott R. Presnell, Monica J. Huber
  • Polynucleotides encoding antagonists of IL-17A, IL-17F, and IL-23p19
    Patent number: 9464134
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: October 11, 2016
    Assignee: ZYMOGENETICS, INC.
    Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, Robert Mabry, Stephen R. Jaspers, Monica J. Huber
  • Methods of treating inflammatory diseases using antibodies that bind both IL-17A and IL-17F
    Patent number: 9416183
    Abstract: The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.
    Type: Grant
    Filed: September 23, 2014
    Date of Patent: August 16, 2016
    Assignee: ZymoGenetics, Inc.
    Inventors: Stephen R. Jaspers, Scott R. Presnell, Monica J. Huber
  • Anti-human IL-21 antibodies
    Patent number: 9388241
    Abstract: Monoclonal antibodies are identified that bind the IL-21 protein. These antibodies are used to identify regions of the IL-21 protein to where binding neutralizes IL-21 activity. Hybridomas and methods of producing anti-IL-21 monoclonal antibodies are described. The monoclonal antibodies are useful in treating IL-21-mediated diseases, which may include autoimmune and inflammatory diseases such as pancreatitis, type I diabetes (IDDM), Graves Disease, inflammatory bowel disease (IBD), Crohn's Disease, ulcerative colitis, irritable bowel syndrome, multiple sclerosis, rheumatoid arthritis, diverticulosis, systemic lupus erythematosus, psoriasis, ankylosing spondylitis, scleroderma, systemic sclerosis, psoriatic arthritis, osteoarthritis, atopic dermatitis, vitiligo, graft vs. host disease (GVHD), cutaneous T cell lymphoma (CTCL), Sjogren's syndrome, glomerulonephritis, IgA nephropathy, transplant rejection, atopic dermatitis, anti-phospholipid syndrome, and asthma, and other autoimmune diseases.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: July 12, 2016
    Assignee: ZymoGenetics, Inc.
    Inventors: Pallavur V. Sivakumar, Stephen R. Jaspers
  • ANTIBODIES THAT BIND BOTH IL-17A AND IL-17F AND METHODS OF USING SAME
    Publication number: 20160053008
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, as well as methods of using the same in inflammation.
    Type: Application
    Filed: November 4, 2015
    Publication date: February 25, 2016
    Inventors: Stephen R. Jaspers, Scott R. Presnell
  • POLYNUCLEOTIDES ENCODING ANTAGONISTS OF IL-17A, IL-17F, AND IL-23P19
    Publication number: 20150197566
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
    Type: Application
    Filed: February 20, 2015
    Publication date: July 16, 2015
    Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, Robert Mabry, Stephen R. Jaspers, Monica J. Huber
  • Antagonists of IL-17A, IL-17F, and IL-23P19
    Patent number: 8992922
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
    Type: Grant
    Filed: June 27, 2013
    Date of Patent: March 31, 2015
    Assignee: ZymoGenetics, Inc.
    Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, Robert Mabry, Stephen R. Jaspers, Monica J. Huber
  • METHODS OF TREATING INFLAMMATORY DISEASES USING ANTIBODIES THAT BIND BOTH IL-17A AND IL-17F
    Publication number: 20150010553
    Abstract: The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.
    Type: Application
    Filed: September 23, 2014
    Publication date: January 8, 2015
    Inventors: STEPHEN R. JASPERS, SCOTT R. PRESNELL, MONICA J. HUBER